- Trials with a EudraCT protocol (950)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
950 result(s) found for: Human tissue.
Displaying page 1 of 48.
EudraCT Number: 2015-003674-32 | Sponsor Protocol Number: 1.1:12-6-2015 | Start Date*: 2016-02-23 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The effect of Telmisartan on inflammatory processes in the vascular wall of abdominal aortic aneurysms. | ||
Medical condition: Abdominal aortic aneurysm with an indication for elective open surgical repair. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000108-42 | Sponsor Protocol Number: V505-001 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particl... | |||||||||||||
Medical condition: vaccination against HPV infection/related disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000109-19 | Sponsor Protocol Number: V502-001 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58... | |||||||||||||
Medical condition: vaccination against HPV infection/related disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003239-38 | Sponsor Protocol Number: PH-L19TNFDOX2-03/16 | Start Date*: 2017-07-28 | ||||||||||||||||
Sponsor Name:Philogen S.p.A. | ||||||||||||||||||
Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien... | ||||||||||||||||||
Medical condition: Unresectable or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000497-30 | Sponsor Protocol Number: FIS-VED-2017-01 | Start Date*: 2018-05-28 | |||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI) | |||||||||||||
Full Title: Phase II clinical trial to evaluate the safety and efficacy of Vedolizumab combined with antiretroviral treatment to achieve functional healing in people infected with HIV-1 without previous antire... | |||||||||||||
Medical condition: Adult patients infected with HIV and without previous antiretroviral treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004750-15 | Sponsor Protocol Number: AIO-STS-0415 | Start Date*: 2017-10-06 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. | ||||||||||||||||||
Medical condition: advanced or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005159-34 | Sponsor Protocol Number: IG1103 | Start Date*: 2014-06-16 |
Sponsor Name:Instituto Grifols, S.A. | ||
Full Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Soft Tissue Open Surgeries | ||
Medical condition: Treatment of haemorrhage resulting from soft tissue surgical procedure | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003796-22 | Sponsor Protocol Number: IFCT-1602 | Start Date*: 2017-09-22 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial | ||||||||||||||||||
Medical condition: Advanced non small cell lung cancer in VIH+ patient | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003581-20 | Sponsor Protocol Number: ALPHA | Start Date*: 2023-03-21 |
Sponsor Name:Medical University Vienna | ||
Full Title: Albendazole pharmacokinetics in plasma, intra-cystic fluid, and cystic tissue of human cystic and alveolar echinococcosis | ||
Medical condition: Albendazole is an orally administered broad-spectrum anthelmintic Drug used in treatment of human alveolar and cystic echinococcosis. To date, data on albendazole and tissue pharmacokinetics are li... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002314-39 | Sponsor Protocol Number: Semaglutide2019 | Start Date*: 2021-07-08 | ||||||||||||||||
Sponsor Name:University College Dublin (UCD) | ||||||||||||||||||
Full Title: A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity | ||||||||||||||||||
Medical condition: Human immunodeficiency virus (HIV) Infection and Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024290-40 | Sponsor Protocol Number: CAH/Ulc/2010 | Start Date*: 2012-12-04 | |||||||||||
Sponsor Name:FUNDACIÓN PROGRESO Y SALUD | |||||||||||||
Full Title: Multicenter clinical trial to evaluate the safety and feasibility of allogeneic tissue engineered product (human nanostructured artificial cornea) in patients with advanced corneal trophic ulcers r... | |||||||||||||
Medical condition: trophic corneal ulcers refractaries to conventional treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004835-39 | Sponsor Protocol Number: 400-08-002 | Start Date*: 2008-11-13 |
Sponsor Name:OMRIX biopharmaceuticals Ltd | ||
Full Title: A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Severe Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvi... | ||
Medical condition: Patients undergoing abdominal, pelvic, retroperitoneal, and (non-cardiac) thoracic surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004104-19 | Sponsor Protocol Number: PH-L19TNFSARC-03/18 | Start Date*: 2020-02-12 | |||||||||||
Sponsor Name:Philogen S.p.A. | |||||||||||||
Full Title: A randomized study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced stage or metastatic soft-... | |||||||||||||
Medical condition: Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004331-39 | Sponsor Protocol Number: INDOOR | Start Date*: 2015-01-02 | |||||||||||
Sponsor Name:Fundació Vall Hebron Institut de Recerca | |||||||||||||
Full Title: HIV Reservoir Dynamics After Switching To Dolutegravir in Patients on a PI/r Based Regimen. A Phase IV Open Randomized Trial | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000826-39 | Sponsor Protocol Number: S-20130165 | Start Date*: 2014-06-17 | |||||||||||
Sponsor Name:Ortopædkirurgisk afdeling Odense Universitetshospital | |||||||||||||
Full Title: Determining the tissue concentration of dicloxacillin using Microdialysis (on healthy male subjects) | |||||||||||||
Medical condition: The trial is conducted on healthy male volunteers. An intravenous dose of 2 grams of dicloxacillin is administered intravenously and the muscle- and subcutaneous tissue concentrations are measured ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2013-005128-40 | Sponsor Protocol Number: IG1102 | Start Date*: 2014-06-16 |
Sponsor Name:Instituto Grifols, S.A. | ||
Full Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surge... | ||
Medical condition: Treatment of haemorrhage resulting from parenchymous tissue surgical procedure | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000941-11 | Sponsor Protocol Number: GMRA-102,Am.No.1 | Start Date*: 2013-03-27 |
Sponsor Name:Bracco Imaging S.p.A. | ||
Full Title: A PROSPECTIVE MULTICENTER COHORT STUDY EVALUATING THE LONG TERM RETENTION OF GADOLINIUM IN HUMAN BONE AND SKIN AFTER THE RETROSPECTIVE ADMINISTRATION OF MULTIHANCE® OR PROHANCE® IN COMPARISON WITH... | ||
Medical condition: Nephrogenic Systemic Fibrosis (NSF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005045-17 | Sponsor Protocol Number: 74983 | Start Date*: 2022-04-05 |
Sponsor Name:AMC | ||
Full Title: Resuscitation for repair of endothelial permeability in endotoxemia | ||
Medical condition: Acute critical illnes requiring volume resuscitation with fluids (e.g. Sepsis). | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003648-55 | Sponsor Protocol Number: EZH-301 | Start Date*: 2020-08-17 | ||||||||||||||||
Sponsor Name:Epizyme, Inc. | ||||||||||||||||||
Full Title: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | ||||||||||||||||||
Medical condition: Phase 1b: Have histologically confirmed Soft tissue sarcoma (STS). Phase 3: Morphology and immunophenotypic panel consistent with epithelioid sarcoma (eg, CD34, epithelial membrane antigen [EMA], ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001885-14 | Sponsor Protocol Number: HN010/HTF-003 | Start Date*: 2005-08-24 |
Sponsor Name:Henogen s.a. | ||
Full Title: A phase II, randomised, double blind, matched pair, controlled study to assess the safety and efficacy of Henogen recombinant soluble human tissue factor (rshTF) on the mandible bone consolidation... | ||
Medical condition: Orthognathic surgery, cases of Bilateral Sagittal Split Osteotomy (B.S.S.O) of the mandible to achieve facial and occlusal balance. This could create bone gaps or continuity defects. These bone gap... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
